All In Biotech

Drug Trial Radar · NCT07933055

Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan or TROP2 ADC) in Advanced or Metastatic EGFR Mutated NSCLC

A Multicenter, Open-label, Multi-cohort, Phase 1b/2 Study to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With Topoisomerase I Inhibitor-based Therapies (Irinotecan or TROP2 ADC) in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Mutations Following Progression on Prior Targeted Therapy

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Oct 8, 2026

Primary completion

Sep 30, 2028

Study completion Mar 31, 2029

Sponsor

Lead sponsor
Txinno Bioscience Inc.Industry
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, multi-cohort, Phase 1b/2 clinical study. This study evaluates TXN10128 in combination with either irinotecan (a topoisomerase I inhibitor) or a TROP2-directed antibody-drug conjugate (TROP2 ADC) in participants with advanced or metastatic NSCLC with confirmed EGFR mutations. The study consists of three cohorts. It enrolls participants who have progressed after prior treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI) and platinum-based doublet chemotherapy. Part B enrolls participants who are currently receiving TROP2 ADC therapy or whose disease has progressed following such therapy (with no restriction on the number of prior lines). In Part C, participants who are naïve to TROP2 ADC therapy and have received no more than three prior lines of systemic anticancer therapy will be enrolled. A safety run-in will first be conducted to confirm the safety of the combination with a TROP2 ADC. Based on the results, the Safety Review Committee (SRC) will select the recommended dose for expansion phase, which will follow Simon's two-stage design.

Conditions

  • NSCLC (Non-small Cell Lung Cancer)

Interventions

  • TXN10128Drug

    oral ENPP1 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: From enrollment until disease progression or the end of the study; tumor assessments every 8 weeks through Week 24 and every 12 weeks thereafter.

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Ajou University Hospital

    Gyeonggi-do, South Korea · Recruiting

  • Seoul University Bundang Hospital

    Gyeonggi-do, South Korea · Recruiting

  • The Catholic University of Korea, ST. Vincent's Hospital

    Gyeonggi-do, South Korea · Not yet recruiting

  • Gachon University Gil Medical Center

    Incheon, South Korea · Recruiting

  • HanYang Univ. Hospital

    Seoul, South Korea · Recruiting

  • Korea University Guro Hospital

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Not yet recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.